Form 4: EyePoint Pharmaceuticals Director David R. Guyer Executes Stock Options and Sells Shares
SEC Form 4
David R. Guyer, a director at EyePoint Pharmaceuticals, exercised stock options and sold shares of common stock on June 3, 2024.
Summary
- On June 3, 2024, David R. Guyer, a director of EyePoint Pharmaceuticals, exercised stock options to acquire 6,525 shares at $3.26 and 3,250 shares at $3.50.
- Following the exercise of these options, Guyer sold 11,625 shares at a weighted average price of $10.2972, with individual prices ranging from $10.00 to $10.87.
- After these transactions, Guyer directly owns 3,700 shares of EyePoint Pharmaceuticals common stock and holds options to purchase 19,550 more shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company director, with neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company directors.
Key Dates
| Date | Description |
|---|---|
| 01/06/2024 | Date exercisable for some stock options |
| 02/23/2024 | Date exercisable for some stock options |
| 06/03/2024 | Date of transaction: exercise of stock options and sale of shares |
| 06/04/2024 | Date of signature for the Form 4 filing |
| 06/19/2033 | Expiration date for stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.